NCT00669591 - A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

August 31, 2010

Conditions

Breast Cancer

Interventions

DRUG

Bavituximab

Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.

Trial Locations (4)

6000

Ltd. Oncological Center, Batumi

0177

JSC. National Cancer Centre, Lisi Lake

0171

Ltd. Tbilisi Oncological Dispensary, Tbilisi

0176

Ltd. Chemotherapy and Immunotherapy clinic Medulla 6, Jikia Str, Tbilisi